Iclaprim: Ph III REVIVE-1 data

Top-line data from the double-blind, international Phase III REVIVE-1 trial in 598 patients with ABSSSIs showed that 80 mg IV iclaprim every 12 hours for 5-14 days met the primary endpoint of non-inferiority to vancomycin in

Read the full 364 word article

User Sign In